Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study

Highlights • Retrospective data of 3756 patients with T2DM on SU monotherapy. • Vildagliptin resulted in better glycaemic control without tolerability issues than other OADs as add-on to SU. • Present analysis supports the use of DPP-4 inhibitors for treatment intensification of first-line SU if met...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Primary care diabetes 2016-12, Vol.10 (6), p.452-458
Hauptverfasser:	Prasanna Kumar, K.M, Phadke, U, Brath, H, Gawai, A, Paldánius, P.M, Mathieu, C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adamantane - administration & dosage Adamantane - adverse effects Adamantane - analogs & derivatives Administration, Oral Adult Aged Biomarkers - blood Blood Glucose - drug effects Blood Glucose - metabolism Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Drug Therapy, Combination Endocrinology & Metabolism Female Glycated Hemoglobin A - metabolism Humans Hyperglycemia - chemically induced Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects India Internal Medicine Logistic Models Male Middle Aged Multivariate Analysis Nitriles - administration & dosage Nitriles - adverse effects Odds Ratio Prospective Studies Pyrrolidines - administration & dosage Pyrrolidines - adverse effects Real-life setting Risk Factors Sulfonylurea Compounds - administration & dosage Sulfonylurea Compounds - adverse effects Sulphonylurea Time Factors Treatment Outcome Vildagliptin Weight Gain - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Retrospective data of 3756 patients with T2DM on SU monotherapy. • Vildagliptin resulted in better glycaemic control without tolerability issues than other OADs as add-on to SU. • Present analysis supports the use of DPP-4 inhibitors for treatment intensification of first-line SU if metformin is not an option.
ISSN:	1751-9918 1878-0210
DOI:	10.1016/j.pcd.2016.06.001